9 results match your criteria Advances in Enzyme Research

  • Page 1 of 1

Regulation of plasminogen activation on cell surfaces and fibrin.

J Thromb Haemost 2018 May 20. Epub 2018 May 20.

Department of Medical Physiology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

The fibrinolytic system dissolves fibrin and maintains vascular patency. Recent advances in imaging analyses allowed visualization of the spatiotemporal regulatory mechanism of fibrinolysis, as well as its regulation by other plasma hemostasis cofactors. Vascular endothelial cells (VECs) retain tissue-type plasminogen activator (tPA) after secretion and maintain high plasminogen (plg) activation potential on their surfaces. Read More

View Article
May 2018
9 Reads

Alpha-1-antitrypsin deficiency: Genetic variations, clinical manifestations and therapeutic interventions.

Mutat Res 2017 07 18;773:14-25. Epub 2017 Mar 18.

Department of Biotechnology, University of Kashmir, Srinagar, Jammu and Kashmir, India. Electronic address:

Alpha-1-antitrypsin (AAT) is an acute phase secretory glycoprotein that inhibits neutrophil proteases like elastase and is considered as the archetype of a family of structurally related serine-protease inhibitors termed serpins. Serum AAT predominantly originates from liver and increases three to five fold during host response to tissue injury and inflammation. The AAT deficiency is unique among the protein-misfolding diseases in that it causes target organ injury by both loss-of-function and gain-of-toxic function mechanisms. Read More

View Article
July 2017
49 Reads

Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.

Exp Hematol 2017 06 22;50:13-21. Epub 2017 Mar 22.

Department of Microbiology & Immunology, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address:

Dysregulation of the mechanistic target of rapamycin complex 1 (mTORC1)-p70 ribosomal protein kinase 1 (S6K1) signaling pathway occurs frequently in acute myeloid leukemia (AML) patients. This pathway also plays a critical role in maintaining normal cellular processes. Given the importance of leukemia stem cells (LSCs) in the development of minimal residual disease, it is critical to use therapeutic interventions that target the LSC population to prevent disease relapse. Read More

View Article

Molecular advancements in the development of thermostable phytases.

Appl Microbiol Biotechnol 2017 Apr 23;101(7):2677-2689. Epub 2017 Feb 23.

Communicable Disease Research Laboratory, St. Joseph's College, Irinjalakuda, India.

Since the discovery of phytic acid in 1903 and phytase in 1907, extensive research has been carried out in the field of phytases, the phytic acid degradatory enzymes. Apart from forming backbone enzyme in the multimillion dollar-based feed industry, phytases extend a multifaceted role in animal nutrition, industries, human physiology, and agriculture. The utilization of phytases in industries is not effectively achieved most often due to the loss of its activity at high temperatures. Read More

View Article
April 2017
3 Reads

Differentiation of human skin-derived precursor cells into functional islet-like insulin-producing cell clusters.

In Vitro Cell Dev Biol Anim 2015 Jun 29;51(6):595-603. Epub 2015 Jan 29.

Department of Biology, Faculty of Sciences, Razi University, Kermanshah, Iran.

Advances in cell-replacement strategies for diabetes have focused on renewable sources of glucose-responsive, insulin-producing cells (IPCs). One of the most proper alternatives is multipotent skin-derived precursors cells (SKPs), which can be differentiated into IPCs. In this study, we reported the isolation and expansion of human skin-derived precursors (hSKPs) followed by their differentiation into IPCs in vitro, through exposure to suitable differentiation factors. Read More

View Article
June 2015
3 Reads

CYP17A1 inhibitors in castration-resistant prostate cancer.

Steroids 2015 Mar 3;95:80-7. Epub 2015 Jan 3.

Scott Department of Urology and The Center for Reproductive Medicine, and the Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, United States. Electronic address:

The majority of prostate cancer (PCa) cases are diagnosed as a localized disease. Definitive treatment, active surveillance or watchful waiting are employed as therapeutic paradigms. The current standard of care for the treatment of metastatic PCa is either medical or surgical castration. Read More

View Article
March 2015
5 Reads

Comparison of Substrate Specificity of -Aminobenzoyl-Glutamate Hydrolase with Carboxypeptidase G.

Adv Enzyme Res 2014 Mar;2(1):39-48

Department of Biochemistry, Chicago College of Osteopathic Medicine, Midwestern University, Downers Grove, IL, USA.

Reduced folic acid derivatives support biosynthesis of DNA, RNA and amino acids in bacteria as well as in eukaryotes, including humans. While the genes and steps for bacterial folic acid synthesis are known, those associated with folic acid catabolism are not well understood. A folate catabolite found in both humans and bacteria is -aminobenzoyl-glutamate (PABA-GLU). Read More

View Article
March 2014
1 Read

Letter to Editor.

Authors:
Amosy E M'Koma

Adv Enzyme Res 2013;1(4):77-78

School of Medicine, Meharry Medical College, Nashville, USA:

View Article
January 2013
3 Reads

Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.

Toxicol In Vitro 2006 Mar 15;20(2):176-86. Epub 2005 Nov 15.

Forest Research Institute, A Division of Forest Laboratories, Inc., Harborside Financial Center, Plaza V, Jersey City, NJ 07311, USA.

Cancer chemotherapeutic prodrugs, such as the oxazaphosphorines cyclophosphamide and ifosfamide, are metabolized by liver cytochrome P450 enzymes to yield therapeutically active, cytotoxic metabolites. The effective use of these prodrugs is limited by host toxicity associated with the systemic distribution of cytotoxic metabolites formed in the liver. This problem can, in part, be circumvented by implementation of cytochrome P450 gene-directed enzyme prodrug therapy (P450 GDEPT), a prodrug activation strategy for cancer treatment that augments tumor cell exposure to cytotoxic drug metabolites generated locally by a prodrug-activating cytochrome P450 enzyme. Read More

View Article
March 2006
5 Reads
  • Page 1 of 1